Laurel Wealth Advisors LLC Increases Stock Holdings in Novo Nordisk A/S $NVO

Laurel Wealth Advisors LLC increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 6,802.0% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 224,661 shares of the company’s stock after acquiring an additional 221,406 shares during the period. Laurel Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $15,506,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Stone House Investment Management LLC purchased a new stake in shares of Novo Nordisk A/S during the first quarter valued at approximately $30,000. NewSquare Capital LLC grew its holdings in Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after purchasing an additional 282 shares in the last quarter. Disciplina Capital Management LLC lifted its holdings in Novo Nordisk A/S by 162.3% in the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after buying an additional 297 shares in the last quarter. Dagco Inc. acquired a new position in Novo Nordisk A/S in the 1st quarter worth $35,000. Finally, Mid American Wealth Advisory Group Inc. purchased a new position in Novo Nordisk A/S in the 2nd quarter valued at about $37,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. BNP Paribas Exane raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 target price on the stock in a research report on Wednesday, August 13th. HSBC lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Sanford C. Bernstein upgraded Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, September 9th. Finally, Barclays restated an “equal weight” rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $57.40.

Novo Nordisk A/S Trading Up 3.6%

NYSE:NVO opened at $48.75 on Thursday. The company has a market cap of $217.67 billion, a PE ratio of 13.39, a P/E/G ratio of 2.33 and a beta of 0.65. The business’s 50 day moving average is $53.32 and its two-hundred day moving average is $59.93. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 52 week low of $43.08 and a 52 week high of $112.52.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The business had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. On average, analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.